A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, Price AM, Andujar C, Dutton M, Webster R, Webb DJ, Semple S, MacIntyre I, Melville V, Wilkinson IB, Hiemstra TF, Wheeler DC, Herrey A, Grant M, Mehta S, Ives N, Townend JN.
Hayer MK, et al. Among authors: wilkinson ib.
Am Heart J. 2017 Sep;191:37-46. doi: 10.1016/j.ahj.2017.05.008. Epub 2017 May 24.
Am Heart J. 2017.
PMID: 28888268
Free PMC article.
Clinical Trial.